Sotirios George Stergiopoulos
PersonHeard in 2 episodes across 1 show since May 2026
Sotirios George Stergiopoulos is a physician, medical researcher, and biotechnology executive who co-founded Coiled Therapeutics PLC, where he serves as Executive Chairman and Chief Medical Advisor. He has also held leadership roles in biotechnology and healthcare and has published research in endocrinology and genetics.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 1 |
| Jun 2026 | 0 |
| Jul 2026 | 1 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
What Sotirios George Stergiopoulos has said on podcasts
11 statements
AO-252 reaches brain tissue at roughly blood-equivalent levels.
“Our ability to actually have pretty much on a 1-to-1 level of what the, the in the blood versus what's in the brain”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 11:03
AO-252 has an approximately 80% clinical benefit rate.
“our clinical benefit rate is at about 80%.”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 13:08
AO-252 reduced a tumor by 30% in a heavily pretreated patient.
“it still takes 30% of the tumor down.”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 13:41
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Sotirios George Stergiopoulos, newest first
